Abstract
Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have